Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Methylphenidate Stories

2010-07-28 11:00:00

BOCA RATON, Fla., July 28 /PRNewswire/ -- Breckenridge announced today that through its agreement with Tris Pharma, the company will market Methylphenidate Solution, the generic version of Methylin® marketed by Shionogi Pharma, Inc., under an Abbreviated New Drug Application (ANDA). Under the terms of this agreement, the products will be manufactured by Tris Pharma, and marketed and distributed by Breckenridge on an exclusive basis in the U.S. The companies plan to start...

2010-07-28 06:00:00

MONMOUTH JUNCTION, N.J., July 28 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved a first-time generic of Methylphenidate Hydrochloride Oral Solution equivalent to brand name Methylin® Oral Solution marketed by Shionogi Pharmaceuticals, Inc. "Tris pursues selective generic opportunities, especially the difficult to formulate or complex...

2010-07-06 16:00:00

DUBLIN and PHILADELPHIA, July 6 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12...

76fc78a0fa0ee5f933feaa03bdf098f81
2010-06-27 13:29:48

A new study shows that use of psychotropic medications during pregnancy increase the probability of birth defects. Researchers at the University of Copenhagen have published an article that documents the serious side effects that can be associated with these types of medications. Between 1998 and 2007, psychotropic medications were associated with 429 adverse drug reactions in Danish children under the age of 17. Researchers from the University of Copenhagen's Faculty of Pharmaceutical...

2010-06-23 14:12:20

Between 1998 and 2007, psychotropic medications were associated with 429 adverse drug reactions (ADRs) in children under 17 in Denmark. Researchers writing in the open access journal BMC Research Notes found that more than half of these were serious and several were birth defects "“ suggesting that tighter controls on the prescription of psychotropic medications to pregnant women may be required. Lise Aagaard and Ebba Holme Hansen from the University of Copenhagen, Denmark, studied all...

7913edf43328c6670895a128a70e46031
2010-06-19 07:40:57

A new study published online in the Journal of Pediatrics suggests that neither attention deficit hyperactivity disorder (ADHD) nor medications used to treat it have a long-term impact on kids' growth. Previous studies have shown that medication may make kids with ADHD eat less and grow slower than their peers that do not have the condition.  According to the Center for Disease Control and Prevention, about 10 percent of boys and 6 percent of girl shave been diagnosed with ADHD. "There...

2010-06-02 20:24:39

Further research is needed Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic (http://www.mayoclinic.org/oncology-rst/) and the North Central Cancer Treatment Group (http://ncctg.mayo.edu/) (NCCTG) recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data...

2010-05-25 15:00:00

NEW ORLEANS, May 25 /PRNewswire/ -- Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD),(1) according to the National Institute of Mental Health (NIMH). New data presented today show efficacy of CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) on ADHD symptoms in children with the condition who...

2010-05-19 08:15:00

PHILADELPHIA, May 19 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, will present scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments Vyvanse® (lisdexamfetamine dimesylate) Capsules CII and INTUNIV(TM) (guanfacine) Extended Release Tablets at two national scientific meetings for psychiatrists May 20-26, 2010 in New Orleans, LA. "We believe that the Vyvanse and INTUNIV study...

2010-05-13 08:39:32

Several barriers prevent minority children with ADHD from receiving the most effective treatments, according to a new study by Michigan State University researchers. In the May issue of the Journal of Attention Disorders, the researchers argue schools and communities should do a better job of getting information to minority families about the combined benefit of medication and counseling for attention deficit hyperactivity disorder. "ADHD has multiple causes and multiple treatment approaches...